Akebia Therapeutics Inc (AKBA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John P. Butler
Employees:
430
245 FIRST STREET, SUITE 1100, CAMBRIDGE, MA 02142
617-871-2098

Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.

Data derived from most recent annual or quarterly report
Market Cap 186.431 Million Shares Outstanding188.314 Million Avg 30-day Volume 1.326 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.08
Price to Revenue1.772 Debt to Equity1.318 EBITDA-224.133 Million
Price to Book Value5.0676 Operating Margin-124.9714 Enterprise Value322.789 Million
Current Ratio1.039 EPS Growth0.388 Quick Ratio0.771
1 Yr BETA 2.0752 52-week High/Low 1.84 / 0.24 Profit Margin-133.2502
Operating Cash Flow Growth-129.1599 Free Cash Flow to Firm (FCFF) TTM -131.596 Million Free Cash Flow to Equity (FCFE) TTM-185.21 Million
Altman Z-Score-4.5857
View SEC Filings from AKBA instead.

View recent insider trading info

Akebia Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AKBA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AKBA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-01 by SNOW ELLEN
  • 3: filed on 2023-07-18 by SNOW ELLEN
  • 4: filed on 2023-06-08 by FRIESON RON
  • 4: filed on 2023-06-08 by WOLF MYLES
  • 4: filed on 2023-06-08 by SMITH CYNTHIA
  • 4: filed on 2023-05-25 by HADAS NICOLE R.
  • 4: filed on 2023-05-25 by DAHAN MICHEL
  • 4: filed on 2023-05-18 by BURKE STEVEN KEITH
  • 4: filed on 2023-05-18 by SPELLMAN DAVID A
  • 4: filed on 2023-05-16 by HADAS NICOLE R.

    • Events (8k)

  • 8-K: filed on 2023-11-21:
    Item 8.01: Other Events
  • 8-K: filed on 2023-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-02:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2023-10-25:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-09-26:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-25:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-17:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-25:
  • 144: filed on 2023-05-16:
  • 144: filed on 2023-05-16:
  • 144: filed on 2023-05-25:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SNOW ELLEN SVP, CFO AND TREASURER

    • Officer
    		 370,000 2023-07-31 2

    ZUMWALT LEANNE M

    • Director
    		 43,700 2023-06-06 1

    ROGERS MICHAEL W

    • Director
    		 96,029 2023-06-06 1

    ADAMS ADRIAN

    • Director
    		 134,800 2023-06-06 1

    GILMAN STEVEN C

    • Director
    		 87,130 2023-06-06 1

    SMITH CYNTHIA

    • Director
    		 95,233 2023-06-06 1

    WOLF MYLES

    • Director
    		 67,681 2023-06-06 1

    FRIESON RON

    • Director
    		 43,700 2023-06-06 1

    HADAS NICOLE R. SVP, CHIEF LEGAL OFFICER

    • Officer
    		 524,344 2023-05-24 4

    DAHAN MICHEL SVP, CHIEF OPERATING OFFICER

    • Officer
    		 574,037 2023-05-24 4

    BURKE STEVEN KEITH SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 530,487 2023-05-16 4

    SPELLMAN DAVID A SVP, CFO AND TREASURER

    • Officer
    		 446,483 2023-05-16 4

    BUTLER JOHN P. CEO AND PRESIDENT

    • Officer
    • Director
    		 1,888,728 2023-03-01 3

    COTREAU VIOLETTA SVP, CHIEF ACCOUNTING OFFICER

    • Officer
    		 219,954 2022-05-12 0

    FAULKINGHAM DELL SVP, CCO

    • Officer
    		 554,387 2022-02-28 0

    HEFFERNAN MICHAEL THOMAS

    • Director
    		 68,686 2021-06-02 0

    GOWEN MAXINE

    • Director
    		 72,933 2020-06-05 0

    ENYEDY MARK J

    • Director
    		 51,243 2020-06-05 0

    AMELLO JASON SVP, CFO & TREASURER

    • Officer
    		 189,642 2020-02-28 0

    TUBRIDY KAREN L SVP, CHIEF DEVELOPMENT OFFICER

    • Officer
    		 169,679 2020-02-28 0

    CANUTE SCOTT A

    • Director
    		 33,800 2019-06-06 0

    MORRISON JODIE POPE

    • Director
    		 78,719 2019-06-06 0

    JAIN RITA SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 96,332 2019-04-11 0

    WYZGA MICHAEL S

    • Director
    		 12,500 2018-06-14 0

    SATTER MUNEER A

    • Director
    		 3,049,542 2018-06-14 0

    RENAUD RONALD C JR

    • Director
    		 17,500 2018-06-14 0

    NASH DUANE

    • Director
    		 33,999 2018-06-14 0

    CLAYMAN MICHAEL D.

    • Director
    		 12,500 2018-06-14 0

    MARONI BRADLEY SVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 102,085 2017-02-21 0

    DALAL ANUPAM

    • Director
    		 12,500 2016-06-16 0

    SHALWITZ ROBERT CHIEF MEDICAL OFFICER

    • Officer
    		 0 2014-05-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 22:15:04 UTC 4.0887 1.2313 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 21:45:03 UTC 4.0887 1.2313 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 21:15:04 UTC 4.0887 1.2313 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 20:45:04 UTC 4.0887 1.2313 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 20:15:04 UTC 4.0887 1.2313 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 19:45:03 UTC 4.0887 1.2313 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 19:15:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 18:45:03 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 18:15:03 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 17:45:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 17:15:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 16:45:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 16:15:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 15:45:03 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 15:15:03 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 14:45:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 14:15:04 UTC 4.1824 1.1376 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 13:45:04 UTC 4.697 0.623 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 13:15:03 UTC 4.697 0.623 3700000
    AKEBIA THERAPEUTICS INC AKBA 2023-11-28 12:45:04 UTC 4.697 0.623 3700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund AKBA -603.0 shares, $-4570.74 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund AKBA -143.0 shares, $-1083.94 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund AKBA -574.0 shares, $-4350.92 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AKBA -30000.0 shares, $-34200.0 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments